Skip Navigation

How will the FDA's Modernization Act affect you?

Recent preclinical modernization acts authorize the replacement of animal testing with cell-based assays. Both the FDA and CEPA are enabling the replacement of animal testing with cell-based assays, eliminating the need for drugs to be tested on animals before human trials. The decision stems from the recognition that human tissue-derived cells offer better predictability for clinical outcomes, particularly in cardiac and cancer testing, leading to a more efficient drug development process without animal harm. According to CEPA, “these amendments require the government to support the development and use of scientifically justified alternative methods and strategies to replace, reduce, or refine the use of vertebrate animals in toxicity testing.” [1]

It’s time for something new and Lumencor’s VOLTA Scanner is facilitating that transition. An optical methodology in place of traditional electronic transduction means consistent, controllable, fast results. Now highly transmembrane ion-channel analyses can be both elegant and user-friendly.

The VOLTA Scanner is revolutionizing safety drug profiling. Ask yourself:

  • Is the High-throughput analysis platform for whole cell assays in my lab robust?
  • Are my drug pharmacokinetic data for ion channel targets reproducible and reliable?
  • Am I able to consistently monitor cellular function with sub-millisecond resolution?
  • Is my highly parallel processing of 96 or 384 microplate well formats relatively easy?
  • Can my lab readily proliferate electrophysiology assays into the hands of lesser-skilled technicians such that our results remain prolific and accurate?

If your facilities are struggling with any of these questions, discover the future of Automated Patch Clamping with the VOLTA Scanner. Learn more here.

Learn more about the Modernization Act: